
Valarie E. Bertoglio
Examiner (ID: 9987, Phone: (571)272-0725 , Office: P/1632 )
| Most Active Art Unit | 1632 |
| Art Unit(s) | 1632 |
| Total Applications | 1276 |
| Issued Applications | 614 |
| Pending Applications | 187 |
| Abandoned Applications | 504 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20067114
[patent_doc_number] => 20250205336
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-26
[patent_title] => TARGETING THE PVR AXIS USING CAR T CELL THERAPY AND COMBINATIONS
[patent_app_type] => utility
[patent_app_number] => 18/999456
[patent_app_country] => US
[patent_app_date] => 2024-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1127
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18999456
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/999456 | Targeting the PVR axis using CAR T cell therapy and combinations | Dec 22, 2024 | Issued |
Array
(
[id] => 19872228
[patent_doc_number] => 12265085
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-01
[patent_title] => Method for analyzing content and distribution of microplastics in marine
[patent_app_type] => utility
[patent_app_number] => 18/735079
[patent_app_country] => US
[patent_app_date] => 2024-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 2265
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 509
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18735079
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/735079 | Method for analyzing content and distribution of microplastics in marine | Jun 4, 2024 | Issued |
Array
(
[id] => 19249047
[patent_doc_number] => 20240200034
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => UTERINE-DERIVED REGENERATIVE CELL COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/589909
[patent_app_country] => US
[patent_app_date] => 2024-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45818
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589909
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/589909 | Uterine-derived regenerative cell compositions and uses thereof | Feb 27, 2024 | Issued |
Array
(
[id] => 20238980
[patent_doc_number] => 12419282
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Non-human animals expressing humanized CD3 complex
[patent_app_type] => utility
[patent_app_number] => 18/442444
[patent_app_country] => US
[patent_app_date] => 2024-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 17
[patent_no_of_words] => 12676
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18442444
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/442444 | Non-human animals expressing humanized CD3 complex | Feb 14, 2024 | Issued |
Array
(
[id] => 19586745
[patent_doc_number] => 20240384302
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => EMBRYONIC CELL CULTURES AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/425516
[patent_app_country] => US
[patent_app_date] => 2024-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22273
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425516
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/425516 | EMBRYONIC CELL CULTURES AND METHODS OF USING THE SAME | Jan 28, 2024 | Pending |
Array
(
[id] => 20438672
[patent_doc_number] => 12509499
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-30
[patent_title] => Therapeutic agents
[patent_app_type] => utility
[patent_app_number] => 18/418864
[patent_app_country] => US
[patent_app_date] => 2024-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 29
[patent_no_of_words] => 3183
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18418864
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/418864 | Therapeutic agents | Jan 21, 2024 | Issued |
Array
(
[id] => 19418805
[patent_doc_number] => 20240294928
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => ARTIFICIAL NUCLEIC ACID MOLECULES
[patent_app_type] => utility
[patent_app_number] => 18/415477
[patent_app_country] => US
[patent_app_date] => 2024-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63847
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18415477
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | Jan 16, 2024 | Pending |
Array
(
[id] => 19521312
[patent_doc_number] => 12123024
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-10-22
[patent_title] => Absolute precipitation of exosomes (APEX) isolation
[patent_app_type] => utility
[patent_app_number] => 18/410576
[patent_app_country] => US
[patent_app_date] => 2024-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 24
[patent_no_of_words] => 9121
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18410576
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/410576 | Absolute precipitation of exosomes (APEX) isolation | Jan 10, 2024 | Issued |
Array
(
[id] => 19954421
[patent_doc_number] => 12324818
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-10
[patent_title] => Generation of alveolar epithelial type 1 (AT1) cells
[patent_app_type] => utility
[patent_app_number] => 18/541448
[patent_app_country] => US
[patent_app_date] => 2023-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 121
[patent_figures_cnt] => 129
[patent_no_of_words] => 34106
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541448
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/541448 | Generation of alveolar epithelial type 1 (AT1) cells | Dec 14, 2023 | Issued |
Array
(
[id] => 19034473
[patent_doc_number] => 20240084288
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => METHOD FOR REDUCING IMMUNOGENICITY OF RNA
[patent_app_type] => utility
[patent_app_number] => 18/515879
[patent_app_country] => US
[patent_app_date] => 2023-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18916
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 124
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515879
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/515879 | Method for reducing immunogenicity of RNA | Nov 20, 2023 | Issued |
Array
(
[id] => 19234058
[patent_doc_number] => 20240191250
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => Methods of Treating Muscular Dystrophy
[patent_app_type] => utility
[patent_app_number] => 18/513227
[patent_app_country] => US
[patent_app_date] => 2023-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17240
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18513227
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/513227 | Methods of Treating Muscular Dystrophy | Nov 16, 2023 | Pending |
Array
(
[id] => 19345548
[patent_doc_number] => 20240254511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => NUCLEIC ACID CONSTRUCTS ENCODING REPROGRAMMING FACTORS LINKED BY SELF-CLEAVING PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/508761
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33287
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508761
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/508761 | NUCLEIC ACID CONSTRUCTS ENCODING REPROGRAMMING FACTORS LINKED BY SELF-CLEAVING PEPTIDES | Nov 13, 2023 | Pending |
Array
(
[id] => 19345548
[patent_doc_number] => 20240254511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => NUCLEIC ACID CONSTRUCTS ENCODING REPROGRAMMING FACTORS LINKED BY SELF-CLEAVING PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/508761
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33287
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508761
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/508761 | NUCLEIC ACID CONSTRUCTS ENCODING REPROGRAMMING FACTORS LINKED BY SELF-CLEAVING PEPTIDES | Nov 13, 2023 | Pending |
Array
(
[id] => 19156077
[patent_doc_number] => 20240148784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS
[patent_app_type] => utility
[patent_app_number] => 18/504238
[patent_app_country] => US
[patent_app_date] => 2023-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44270
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504238
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/504238 | METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS | Nov 7, 2023 | Pending |
Array
(
[id] => 19156077
[patent_doc_number] => 20240148784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS
[patent_app_type] => utility
[patent_app_number] => 18/504238
[patent_app_country] => US
[patent_app_date] => 2023-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44270
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504238
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/504238 | METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS | Nov 7, 2023 | Pending |
Array
(
[id] => 19170163
[patent_doc_number] => 20240156137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => COMPOSITIONS AND METHODS FOR PRODUCING NON-HUMAN TISSUE ENGINEERED MEAT PRODUCTS
[patent_app_type] => utility
[patent_app_number] => 18/502249
[patent_app_country] => US
[patent_app_date] => 2023-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502249
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/502249 | COMPOSITIONS AND METHODS FOR PRODUCING NON-HUMAN TISSUE ENGINEERED MEAT PRODUCTS | Nov 5, 2023 | Pending |
Array
(
[id] => 19265622
[patent_doc_number] => 20240209321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => TRANSCRIPTION FACTORS CONTROLLING DIFFERENTIATION OF STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 18/496419
[patent_app_country] => US
[patent_app_date] => 2023-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6175
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18496419
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/496419 | TRANSCRIPTION FACTORS CONTROLLING DIFFERENTIATION OF STEM CELLS | Oct 26, 2023 | Pending |
Array
(
[id] => 19246805
[patent_doc_number] => 20240197789
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => TREATMENT OF CANAVAN DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/488859
[patent_app_country] => US
[patent_app_date] => 2023-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14533
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488859
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/488859 | TREATMENT OF CANAVAN DISEASE | Oct 16, 2023 | Pending |
Array
(
[id] => 19246805
[patent_doc_number] => 20240197789
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => TREATMENT OF CANAVAN DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/488859
[patent_app_country] => US
[patent_app_date] => 2023-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14533
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488859
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/488859 | TREATMENT OF CANAVAN DISEASE | Oct 16, 2023 | Pending |
Array
(
[id] => 19020177
[patent_doc_number] => 20240076348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => THERAPEUTIC AGENTS
[patent_app_type] => utility
[patent_app_number] => 18/472441
[patent_app_country] => US
[patent_app_date] => 2023-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7871
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472441
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/472441 | THERAPEUTIC AGENTS | Sep 21, 2023 | Pending |